TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11742706
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus vinorelbine (G+V)
Study: 29677302
Drug: Perioperative behavioral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative behavioral therapy and pelvic floor muscle training (BPMT)
Study: 10647316
Drug: Spinal manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulation plus soft tissue therapy
Study: 10647316
Drug: Soft tissue
Normalized name: INSULIN DETEMIR 14.2 mg in 1 mL SOFT TISSUE IMPLANT [Levemir]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft tissue therapy plus low-power laser therapy
Study: 31858186
Drug: Praliciguat 40
Normalized name: Praliciguat
DrugBank: Praliciguat (DB16300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praliciguat 40 mg once daily for days 1-14
Study: 25668198
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (1 mg/m²/day) for 4 years
Study: 25668198
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (1 mg/m²/day) for 9 years
Study: 25668198
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (1 mg/m²/day) during adolescence
Study: 20513828
Drug: Referred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referred treatment
Study: 16884345
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or repeated doses of kudzu extract
Study: 16884345
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of kudzu extract
Study: 11503796
Drug: Levonorgestrel (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel (750 mug per dose)
Study: 11503796
Drug: Ethinyloestradiol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyloestradiol (100 mug) + Levonorgestrel (500 mug) combination
Study: 9365449
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (0.25% 4-7 mL/h) and morphine (0.16-0.28 mg/h) for 18 h before and during the operation
Study: 9365449
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline (4-7 mL/h) and oral or intramuscular morphine
Study: 7999656
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine and morphine
Study: 9365449
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline and oral or intramuscular morphine
Study: 1300984
Drug: rHu-EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rHu-EPO treatment
Study: 3465056
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of lidocaine
Study: 20704666
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of saline
Study: 3465056
Drug: Both lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both lidocaine and saline injections
Study: 25008880
Drug: High-dose BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: High-dose BTX-A (6 U/kg) in group B1 (n=55)
Study: 25008880
Drug: Low-dose BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Low-dose BTX-A (3 U/kg) in group B2 (n=54)
Study: 25008880
Drug: High-dose BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: High-dose BTX-A (6 U/kg) in group A1 (n=73)
Study: 25008880
Drug: Low-dose BTX-A
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Low-dose BTX-A (3 U/kg) in group A2 (n=74)
Study: 18649869
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration (Control)
Study: 19651523
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel
Study: 18420499
Drug: Paclitaxel every
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel every 3 weeks (standard therapy)
Study: 20707781
Drug: Naltrexone implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone implants
Study: 11778513
Drug: Oral sustained
Normalized name: Sustain Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained release theophylline (Protheo) (200 mg/night) and inhaled BDP (300 micrograms/day)
Study: 11778513
Drug: Inhaled BDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled BDP (600 micrograms/day) and oral placebo
Study: 30110719
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Co2+ single oral dosage
Study: 30110719
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Co2+ single oral dosage
Study: 30110719
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Co2+ daily dosage for five days
Study: 30110719
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Co2+ daily dosage for five days
Study: 30207920
Drug: Fingolimod (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (0.5 mg per day; 0.25 mg per day for patients with body weight ≤40 kg)
Study: 30207920
Drug: Interferon beta‐1a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta‐1a (30 μg per week)
Study: 27456005
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL flush every 24 hours
Study: 27456005
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL flush every 6 hours
Study: 27456005
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL flush every 24 hours
Study: 27456005
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL flush every 6 hours
Study: 24401930
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 and fluorouracil 1000 mg/m2 (120-h infusion every 21 days) for three cycles
Study: 24401930
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and fluorouracil chemotherapy
Study: 17617202
Drug: AFP (cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP (cutoff of 20 ng/mL)
Study: 17617202
Drug: AFP (cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP (cutoff of 200 ng/mL)
Study: 17617202
Drug: AFP-L3% (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP-L3% (in patients with elevated AFP 20-200 ng/mL)
Study: 15882523
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination with HPV16 VLPs
Study: 12414850
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ERT/HRT and calcitriol
Study: 10782805
Drug: Infliximab (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5, 10, or 20 mg/kg)
Study: 8557883
Drug: Trazodone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone treatment
Study: 508506
Drug: Triprolidine hydrochloride
Normalized name: Triprolidine Hydrochloride
DrugBank: Triprolidine (DB00427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triprolidine hydrochloride (2.5 mg)
Study: 508506
Drug: Triprolidine hydrochloride
Normalized name: Triprolidine Hydrochloride
DrugBank: Triprolidine (DB00427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triprolidine hydrochloride (10 mg, sustained release)
Study: 508506
Drug: Brompheniramine maleate
Normalized name: Brompheniramine Maleate
DrugBank: Brompheniramine (DB00835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brompheniramine maleate (4 mg)
Study: 508506
Drug: Brompheniramine maleate
Normalized name: Brompheniramine Maleate
DrugBank: Brompheniramine (DB00835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brompheniramine maleate (12 mg, sustained release)
Study: 21078545
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 and 120 mg/day)
Study: 20030854
Drug: Gastrectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrectomy with metastasectomy plus systemic chemotherapy (GYMS)
Study: 20030854
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone (SA)
Study: 18823466
Drug: Drotrecogin alpha
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alpha activated (DrotAA) treatment
Study: 18823466
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for sepsis without DrotAA
Study: 12077033
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg administered orally once daily
Study: 12077033
Drug: Indometacin 50
Normalized name: Indometacin 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin 50 mg administered orally three times daily
Study: 7608801
Drug: Heparin CVC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin CVC flush solution
Study: 7608801
Drug: Heparin-vancomycin CVC
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin-vancomycin CVC flush solution
Study: 1067402
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (Gly‐Oxide Liquid)
Study: 29141357
Drug: Anticoagulant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant and vasodilator drugs (preventive group)
Study: 29141357
Drug: Anticoagulant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant and vasodilator drugs (treatment group)
Study: 23475029
Drug: S-ketamine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (0.4 mg/kg) as a bolus followed by propofol
Study: 23475029
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by propofol (treatment-as-usual group)
Study: 22321019
Drug: Nicotine spray
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine spray
Study: 18296564
Drug: Aminophylline (inhibits
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (inhibits adenosine receptors)
Study: 8865916
Drug: gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemfibrozil (600 mg/b.i.d.) for three months
Study: 8865916
Drug: simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (10 mg/day) for three months
Study: 6581063
Drug: Fenoterol inhalation
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol inhalation powder (50 + 50 + 100 + 200 micrograms)
Study: 6581063
Drug: Fenoterol inhalation
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol inhalation powder (200 + 50 + 50 + 50 micrograms)
Study: 31781666
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D3 supplementation (50,000 IUs weekly)
Study: 31781666
Drug: Low-dose comparator
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose comparator (5,000 IUs weekly)
Study: 31781666
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (high-dose and low-dose)
Study: 22014532
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (16 sessions of individual cognitive behavior therapy and combination nicotine replacement therapy for 26 weeks)
Study: 22014532
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (referral to a free-standing smoking cessation program with varying duration counseling and medications)
Study: 20697948
Drug: Total glucosides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total glucosides of paeony capsule (TGPC) combined with citirizine (10 mg/day)
Study: 20697948
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (citirizine 10 mg/day)
Study: 11886178
Drug: Pegylated-interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegylated-interferon alpha-2b monotherapy (PMT)
Study: 11886178
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with ribavirin (PCT1-low dose ribavirin and PCT2-high dose ribavirin)
Study: 11886178
Drug: PCT2 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT2 (high dose ribavirin)
Study: 10452749
Drug: MSG 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSG 2.5 g oral challenge
Study: 10452749
Drug: MSG sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSG sensitivity in individuals with aspirin-sensitive asthma (negative history)
Study: 29907964
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of bleomycin (1 mg/ml) every 2 weeks for a maximum of four sessions
Study: 21280519
Drug: Lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 10 mg/d
Study: 21280519
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/d
Study: 17174527
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled intravenous analgesia (PCIA) with piritramide
Study: 9796489
Drug: Combined CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CO2 laser irradiation and fluoridation with stannous fluoride gel
Study: 21316768
Drug: Solution-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused therapy
Study: 16680285
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy session with classical music for 30 minutes
Study: 15294368
Drug: 3-day clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day clomiphene citrate (CC) regimen (50mg per day for 3 days)
Study: 15294368
Drug: 5-day clomiphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day clomiphene citrate (CC) regimen (50mg per day for 5 days)
Study: 11478142
Drug: High-dose MPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MPA (600 mg/day) for over 8 weeks
Study: 11478142
Drug: Cyclic administrations
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic administrations of low-dose MPA after high-dose MPA
Study: 11478142
Drug: MPA as
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA as adjuvant therapy after complete operations and whole pelvic irradiation
Study: 11478142
Drug: MPA in
Normalized name: polyurethane-34 (55 MPA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA in combination with chemotherapy (CAP)
Study: 8859724
Drug: Interferon-gamma (IFN-gamma)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) combination therapy
Study: 8859724
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of tumor-infiltrating lymphocytes (TIL), IL-2, and IFN-gamma
Study: 30609099
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for insomnia (n=106)
Study: 24577747
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (sleep‐related behavior modification and progressive muscle relaxation) for 3 months
Study: 22168538
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg single dose
Study: 22168538
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg single dose
Study: 20645951
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 μg.kg(‐1)
Study: 20645951
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (0.9% saline)
Study: 10349190
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (25 micrograms)
Study: 10349190
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (50 micrograms)
Study: 10349190
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol (100 micrograms)
Study: 8745497
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of glucose controlled by pump
Study: 15969309
Drug: Intranasal phototherapy
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal phototherapy
Study: 16775552
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of vitamin E + 1 g of vitamin C (V; N=15)
Study: 16294572
Drug: Integrated assertive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated assertive community treatment
Study: 11524344
Drug: Metaraminol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaraminol infusion (0.25 mg/min, titrated)
Study: 8513520
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl 100 micrograms intraoperatively, self-administered maximum of two epidural fentanyl boluses 50 micrograms (10 micrograms.ml‐1) with a lockout period of five minutes for a maximum of two doses per hour.
Study: 8513520
Drug: Single bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus of epidural morphine 3 mg (0.5 mg.ml‐1) intraoperatively, with PCA devices filled with 0.9% NaCl.
Study: 28372335
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (40 IU daily for four months)
Study: 28372335
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (40 IU daily for four months)
Study: 20556262
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading group (60 implants)
Study: 20556262
Drug: Delayed loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed loading group (60 implants)
Study: 18480688
Drug: Tiagabine (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (4, 8, or 12 mg/d in fixed-dose study; 4-16 mg/d in flexible-dose trials)
Study: 16878723
Drug: β-blockers therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-blockers therapy
Study: 12509593
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 mL containing 1183 mg DHA)
Study: 12509593
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (10 mL containing 4747 mg linoleic acid)
Study: 11094013
Drug: Thiopental (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (2 mg/kg)
Study: 6356323
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g twice daily)
Study: 20664489
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of olanzapine
Study: 17172427
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg twice daily for 5 to 15 days before surgery
Study: 14517580
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate concentrations (1-100 microg/mL)
Study: 11081318
Drug: Transdermal dihydrotestosterone
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal dihydrotestosterone (DHT) treatment for 12 weeks
Study: 29672831
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg riluzole
Study: 8721257
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg riluzole
Study: 1416129
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia by epidural infusion of buprenorphine (3 micrograms/mL) with 0.03% bupivacaine
Study: 1416129
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia by epidural infusion of fentanyl (2 micrograms/mL) with 0.03% bupivacaine
Study: 3986085
Drug: Oral secoverine
Normalized name: fenoverine
DrugBank: Fenoverine (DB13042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral secoverine hydrochloride